Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announces strong data for KRX-0401 (perifosine) in patients with advanced chronic lymphocytic leukemia (CLL) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE